Bleomycin Sulfate
2 NDCs across 2 manufacturers|2 Generic,0 Brand
Bleomycin Sulfate is used to treat squamous cell carcinoma, choriocarcinoma, hodgkin disease, non-hodgkin lymphoma, melanoma and sarcoma, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved before 1982, and the first generic was approved Jun 1, 1996. In 2024, Medicare Part D spent $1K on Bleomycin Sulfate across 16 claims.
Bleomycin Sulfate is available as 2 NDCs from 2 manufacturers (2 generic, 0 brand), with NADAC prices from $26.45 to $26.45 per EA. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
2
2G / 0B
Manufacturers
2
competing in market
Price Spread
$26.45 – $26.45
per EA
7d Activity
avg +0.0% WoW · of 2 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Manufacturer Breakdown
2 manufacturers producing BLEOMYCIN SULFATE
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
BLEOMYCIN SULFATE 15 UNIT VIAL | $26.4480 per EA | — |
BLEOMYCIN SULFATE 15 UNIT VIAL | $26.4480 per EA | — |
Frequently Asked Questions
What is Bleomycin Sulfate used to treat?
Bleomycin Sulfate is used to treat squamous cell carcinoma, choriocarcinoma, hodgkin disease, non-hodgkin lymphoma, melanoma and sarcoma, per the National Library of Medicine's MED-RT classification.
When did Bleomycin Sulfate become available as a generic?
FDA approved the first generic Bleomycin Sulfate (ANDA) on Jun 1, 1996.
How much does Medicare spend on Bleomycin Sulfate?
In 2024, Medicare Part D spent $1K on Bleomycin Sulfate across 16 claims.
How many Bleomycin Sulfate products are on the market?
The Bleomycin Sulfate drug market contains 2 NDCs from 2 manufacturers — 2 generic and 0 brand products.
What is the price range for Bleomycin Sulfate?
NADAC reference prices for Bleomycin Sulfate range from $26.4480 to $26.4480 per EA.
Which manufacturers make Bleomycin Sulfate?
2 manufacturers list Bleomycin Sulfate in NADAC. Ranked by number of NDCs, the largest are Fresenius Kabi USA, LLC (1), Meitheal Pharmaceuticals Inc. (1).